alreadi
centuri
observ
made
cancer
patient
contract
infecti
diseas
occasion
went
brief
period
clinic
remiss
recogn
contract
influenza
sometim
produc
benefici
effect
leukem
patient
earli
observ
predat
formal
demonstr
influenza
fact
caus
viru
clinic
studi
initi
rang
human
virus
administ
cancer
patient
includ
hbv
west
nile
viru
adenoviru
mump
viru
clinic
experi
approach
discuss
sever
excel
extens
histor
review
although
anecdot
evid
antitumor
efficaci
obtain
side
effect
sever
effort
reduc
side
effect
circumv
inhibitori
effect
brought
neutral
immun
sever
nonhuman
virus
enter
stage
includ
newcastl
diseas
viru
vesicular
stomat
viru
howev
advent
new
cytostat
drug
problemat
attenu
candid
virus
oncolyt
viru
approach
larg
abandon
rise
gene
therapi
clinic
feasibl
approach
treat
human
diseas
led
reviv
oncolyt
viru
therapi
approach
hope
safe
efficaci
use
virus
anticanc
agent
fuell
larg
incident
evid
antitumor
efficaci
well
histori
safe
use
sever
live
viru
vaccin
moreov
recombin
dna
technolog
offer
effect
system
revers
genet
mani
viru
famili
allow
design
new
potenti
efficaci
oncolyt
virus
even
arm
replic
oncolyt
virus
therapeut
transgen
parallel
continu
expand
interest
use
nonhuman
virus
oncolyt
viru
therapi
two
main
reason
interest
first
absenc
immun
nonhuman
virus
human
popul
may
provid
viral
oncolyt
agent
head
start
allow
therapeut
viru
administ
without
risk
preexist
neutral
immun
inactiv
vector
frustrat
transduct
tumor
cell
reason
mani
nonhuman
virus
associ
diseas
human
addit
recombin
dna
technolog
offer
prospect
overcom
limit
impos
viral
pathogen
human
develop
brought
back
biosafeti
issu
regard
biosafeti
three
risk
categori
distinguish
firstli
preclin
phase
hazard
associ
handl
virus
preclin
evalu
program
level
contain
requir
activ
depend
biosafeti
classif
viru
handl
guidelin
current
exist
contain
use
activ
requir
use
dedic
laboratori
guidelin
standard
wide
adopt
clinic
applic
two
distinct
categori
risk
first
visibl
categori
risk
associ
potenti
hazard
patient
receiv
virus
part
therapi
procedur
proper
assess
risk
potenti
benefit
differ
greatli
convent
medic
intervent
howev
addit
patient
risk
fact
therapeut
agent
infecti
potenti
shed
patient
bear
possibl
horizont
transfer
viral
therapeut
agent
latter
risk
categori
clinic
use
virus
summar
term
environment
risk
use
oncolyt
virus
environment
risk
encompass
chanc
sever
undesir
effect
result
clinic
use
therapeut
virus
human
patient
viz
person
will
expos
viral
therapeut
agent
medic
personnel
patient
rel
patient
suscept
anim
eg
pet
anim
livestock
poultri
wildlif
varieti
potenti
environment
hazard
undesir
consequ
wide
rang
patholog
effect
eg
outbreak
infecti
diseas
short
time
scale
tumorform
upon
exposur
murin
leukemia
virus
mulv
longtim
scale
econom
consequ
eg
risk
countri
lose
aujeszki
diseasefre
statu
suid
herpesviru
would
shed
patient
use
oncolyt
virus
therefor
requir
contain
procedur
reduc
transfer
minim
risk
associ
far
best
knowledg
gener
guidanc
exist
estim
evalu
environment
risk
associ
clinic
use
nonhuman
virus
therapeut
agent
exampl
cancer
therapi
absenc
guidelin
assess
environment
risk
seem
odd
specif
regul
place
instanc
xenotransplant
critic
shortag
human
donor
materi
transplant
prompt
use
anim
altern
sourc
cell
tissu
whole
organ
transplant
human
xenotransplant
nonhuman
primat
pig
two
main
sourc
cell
tissu
use
nonhuman
primat
constrain
ethic
consider
small
anatom
size
limit
avail
pig
consid
suitabl
altern
sourc
pig
larg
anatom
physiolog
similar
human
size
organ
circulatori
system
addit
pig
bred
specif
pathogenfre
genet
homogen
herd
major
concern
xenotransplant
potenti
transfer
anim
pathogen
human
recipi
especi
porcin
endogen
retrovirus
provid
potenti
hazard
risk
crossspeci
transmiss
may
increas
immun
suppress
appli
follow
transplant
led
precautionari
approach
instig
moratoria
clinic
trial
involv
xenotransplant
mani
countri
establish
statu
use
nonhuman
replicationcompet
virus
therapeut
applic
oncolyticviru
therapi
perform
literatur
studi
yield
list
differ
nonhuman
viru
speci
consid
futur
clinic
applic
nonhuman
virus
vector
replicationcompet
unmodifi
cell
natur
host
list
replicationdefect
virus
virus
vector
requir
special
helper
function
replic
therefor
replicationincompet
unmodifi
cell
natur
host
exclud
reason
exclud
latter
virus
vector
addit
level
contain
must
reacquir
genet
inform
allow
function
complement
miss
function
result
studi
summar
sever
other
announc
follow
soon
data
reason
assum
next
year
wit
rise
number
clinic
trial
nonhuman
virus
use
therapeut
agent
widespread
clinic
use
virus
may
associ
small
finit
risk
undesir
viral
adapt
zoonot
infect
human
cancer
patient
frequent
compromis
immun
function
may
allow
therapeut
virus
replic
prolong
period
time
eventu
adapt
human
viru
would
would
acquir
capac
spread
horizont
patient
health
care
worker
patient
rel
could
becom
establish
human
popul
although
author
awar
exampl
outbreak
virus
consequ
intent
exposur
human
recent
histori
provid
sever
exampl
spontan
crossspeci
transfer
establish
new
host
exampl
discuss
detail
elsewher
includ
exampl
recent
swine
flu
influenza
viru
sarscorona
viru
distant
past
hiv
lentivirus
risk
transfer
adapt
nonhuman
virus
human
host
led
mani
countri
impos
moratorium
clinic
use
xenotransplant
specif
clinic
use
porcin
tissu
although
wide
consensu
moratorium
xenotransplant
seem
specif
guidanc
develop
clinic
strategi
involv
deliber
administr
nonhuman
virus
therapeut
intent
formul
guidelin
ensur
appropri
assess
risk
patient
environ
may
suitabl
date
guidelin
could
come
either
point
consid
investig
formal
regul
regard
relev
recogn
mani
virus
develop
definit
genet
modifi
organ
gmo
henc
use
may
demand
environment
risk
assess
part
formal
nation
intern
eg
european
gmo
regul
also
emea
ich
consider
document
oncolyt
virus
provid
guidanc
relat
manag
environment
risk
advis
consid
barrier
contracept
durat
clinic
trial
standard
precaut
prevent
persontoperson
transmiss
address
environment
risk
mere
state
mani
consider
might
fall
head
environment
releaserisk
region
author
contact
detail
nevertheless
gmo
guidelin
may
provid
scaffold
formul
guidelin
environment
risk
assess
era
use
nongmo
nonhuman
virus
clinic
trial
assess
patientsafeti
aspect
may
adopt
qualiti
guidelin
establish
evalu
human
vaccin
safeti
element
need
consid
era
similar
gmo
virus
nongmo
virus
figur
show
number
topic
relat
therapeut
virus
intend
use
pertin
cover
era
outlin
larg
number
nonhuman
viru
speci
develop
clinic
viru
requir
artifici
modif
host
rang
wild
type
viru
unabl
infect
human
cell
stage
indic
phase
research
progress
preclin
vitro
clinic
studi
arbitrari
rel
environment
risk
scale
neglig
low
medium
high
high
scale
repres
author
estim
environment
risk
assign
clinic
use
virus
base
aggreg
biolog
paramet
describ
wildtyp
virus
assess
standard
classif
medium
default
class
adjust
factor
posit
neg
affect
risk
environ
public
avail
inform
found
inadequ
score
increas
provid
caution
singl
refer
includ
exampl
research
activ
applic
within
viru
speci
mark
differ
relev
paramet
differ
isol
serotyp
addit
mani
virus
attenu
deriv
isol
use
vaccin
vaccin
strain
properti
differ
significantli
wildtyp
virus
noteworthi
frequent
publish
literatur
provid
insuffici
inform
serotyp
strain
isol
use
studi
frustrat
use
extrapol
data
biolog
characterist
virus
differ
markedli
abl
rank
virus
potenti
hazard
associ
clinic
use
assign
rel
environment
risk
score
viru
speci
consid
clinic
use
score
base
sever
factor
includ
capac
viru
replic
product
human
cell
potenti
amplif
shed
viru
potenti
virolog
biolog
paramet
paramet
relat
potenti
consequ
potenti
consequ
unintend
exposur
nontarget
human
biolog
consequ
unintend
exposur
nonhuman
suscept
host
potenti
econom
consequ
unintend
exposur
nonhuman
suscept
host
paramet
relat
risk
manag
vaccin
avail
use
prophylact
treatment
human
vaccin
avail
use
prophylact
treatment
normal
host
speci
effect
antivir
avail
use
treatment
viral
infect
human
transfer
horizont
occurr
viru
pathogen
addit
potenti
consequ
viru
shed
natur
host
speci
taken
account
avail
regist
vaccin
may
advantag
protect
suscept
host
unlik
situat
shed
lead
infect
nonhuman
host
speci
classif
intend
read
indic
potenti
environment
hazard
associ
viru
independ
applic
absolut
actual
environment
risk
eventu
depend
applic
reduc
instanc
contain
measur
classif
use
five
categori
rel
environment
risk
neglig
low
medium
high
high
medium
categori
use
start
point
classif
assign
scale
base
factor
could
strongli
affect
rel
environment
risk
import
includ
tabl
none
virus
classifi
high
rel
environment
risk
categori
wherea
three
virus
classifi
high
furthermor
two
virus
score
neglig
latter
concern
autographa
californica
baculoviru
canarypox
viru
three
virus
place
high
risk
categori
maraba
viru
seneca
valley
viru
svv
murin
leukemia
viru
mulv
propos
use
virus
classifi
high
rel
environment
risk
score
brief
summari
biosafeti
aspect
present
follow
section
comprehens
descript
nonhuman
virus
develop
clinic
use
research
activ
herewith
motiv
classif
describ
elsewher
virus
place
high
rel
environment
risk
categori
maraba
viru
belong
vesiculovirus
group
rhabdovirida
singl
strain
maraba
viru
bear
isol
pool
femal
phlebotomin
sand
fli
lutzomyia
spp
captur
tree
trunk
serra
nort
municip
maraba
para
state
brazil
anim
human
sera
collect
time
region
amazon
basin
brazil
test
presenc
neutral
antibodi
singl
human
sampl
test
posit
antibodi
maraba
viru
note
region
viru
isol
rel
human
inhabit
viru
replic
sand
fli
follow
experiment
intrathorac
inocul
transovari
transmit
fli
present
known
maraba
viru
caus
diseas
human
howev
kill
newborn
mice
within
h
intracerebr
inocul
also
lethal
adult
mice
administ
intraperiton
maraba
viru
antigen
close
relat
vsvindiana
cocal
alagoa
virus
known
caus
vesicular
diseas
cattl
swine
record
maraba
viru
experiment
administ
domest
anim
aim
expand
current
array
safe
potent
oncolyt
virus
brun
colleagu
maraba
viru
efficaci
syngen
xenogen
tumor
model
anim
receiv
six
system
dose
maraba
select
mutant
see
follow
section
respond
treatment
complet
tumor
regress
durabl
cure
anim
complementari
studi
brun
colleagu
perform
test
use
immunocompet
anim
bear
human
ovarian
xenograft
even
low
dose
pfu
anim
treat
maraba
signific
reduct
tumor
burden
studi
maraba
efficaci
wildtyp
maraba
viru
system
develop
genet
modif
maraba
viru
revers
genet
sever
recombin
strain
maraba
viru
develop
potenti
therapeut
vector
author
explor
two
mutat
previous
identifi
vsv
improv
vsv
replic
cell
result
protein
g
protein
similar
chang
introduc
homolog
posit
maraba
viru
genom
alter
codon
gene
g
gene
respect
doubl
mutant
refer
maraba
show
impair
replic
maraba
attenu
primari
human
skin
fibroblast
remain
strongli
lytic
panel
malign
cell
line
report
use
maraba
viru
oncolyt
agent
human
maraba
viru
well
toler
follow
intraven
inject
immunocompet
balbc
mice
maximum
toler
dose
mtd
maraba
wt
sever
attenu
strain
also
determin
mtd
maraba
mutant
greater
wt
viru
dose
mtd
mice
gener
show
transient
weight
loss
dehydr
resolv
within
day
postinfect
viru
could
detect
brain
mice
euthan
day
later
remain
determin
maraba
viru
transmit
human
come
close
contact
infect
anim
insect
vector
despit
fact
viru
probabl
reli
insect
host
transmiss
suscept
mammal
classifi
rel
environment
risk
high
base
uncertainti
biolog
patholog
maraba
viru
mammalian
host
human
road
develop
particular
viru
clinic
applic
product
usual
long
one
viru
made
remark
fast
progress
toward
clinic
use
svv
viru
first
identifi
contamin
cell
cultur
medium
svv
first
member
new
genu
picornavirida
call
seneca
viru
genu
propos
includ
porcin
picornavirus
share
similar
sequenc
biochem
properti
svv
svv
isol
genet
therapi
inc
gaithersburg
md
cell
cultur
media
contamin
cultiv
cell
presum
introduc
via
bovin
serum
porcin
trypsin
picornalik
virus
isol
pig
show
varieti
clinic
symptom
variou
locat
across
usa
subsequ
studi
demonstr
close
relat
svv
inform
coupl
isol
member
svv
pig
support
hypothesi
pig
possibl
farm
anim
natur
host
svv
analys
serum
sampl
obtain
gener
popul
well
farmer
yield
singl
sampl
contain
lowtit
neutral
antibodi
svv
data
indic
exposur
svv
preval
human
popul
although
svv
infect
human
propag
human
tumor
cell
show
neuroendocrin
featur
cytolyt
potenti
select
svv
determin
neuroendocrin
pediatr
tumor
cell
line
normal
cell
svv
found
strongli
cytotox
especi
smallcel
lung
cancer
cell
line
pediatr
solid
tumor
cell
viru
may
suitabl
intraven
deliveri
human
viru
prone
inhibit
compon
human
blood
properti
exploit
develop
svv
oncolyt
agent
recent
phasei
trial
evalu
safeti
ssv
dose
escal
studi
viru
administ
intraven
patient
advanc
cancer
doselimit
toxic
encount
current
three
clinic
studi
evalu
safeti
activ
svv
includ
studi
young
patient
year
age
evalu
abil
svvadapt
replic
nonpermiss
cell
reddi
colleagu
perform
experi
viru
passag
intent
three
time
nonpermiss
cell
line
progeni
viru
produc
suggest
svv
chang
tropism
addit
antibodyescap
mutant
svv
produc
cell
viru
grown
media
contain
antisvv
mous
hyperimmun
serum
although
data
suggest
genom
svv
stabl
note
similar
rna
virus
genet
variabl
picornavirus
kopperslal
r
c
hoeben
high
like
new
quasispeci
frequent
gener
determin
whether
svv
horizont
transmit
studi
perform
mice
inject
svv
hous
mix
mice
day
mice
seroconvert
provid
evid
absenc
horizont
viru
transmiss
interestingli
analys
viral
sequenc
variou
isol
fall
evolutionari
time
line
suggest
virus
recent
common
ancestor
possibl
origin
earli
sinc
virus
isol
sampl
collect
divers
geograph
area
usa
result
suggest
recent
introduct
viru
us
porcin
popul
base
observ
introduct
svv
human
popul
medic
treatment
cautious
monitor
clear
svv
found
pig
usa
howev
attempt
infect
pig
two
field
isol
fail
reveal
patholog
importantli
phylogenet
studi
suggest
viru
may
recent
introduc
pig
popul
although
possibl
svv
exist
porcin
popul
elsewher
world
also
conceiv
viru
enter
us
porcin
popul
anoth
host
altern
host
could
rodent
speci
sinc
svv
closest
rel
cardiovirus
virus
rodent
despit
avail
preliminari
safeti
data
initi
clinic
studi
limit
inform
suscept
mammalian
speci
svv
uncertainti
natur
host
absenc
shed
data
publish
literatur
led
us
classifi
svv
high
rel
environment
risk
score
mulv
belong
genu
gammaretroviru
mulv
wide
distribut
domest
feral
mice
mous
strain
carri
genet
inform
mulvrel
virus
endogen
virus
genom
dna
endogen
virus
product
rare
germlin
infect
result
mendelian
transmiss
integr
provirus
progeni
endogen
mulv
provirus
replicationdefect
although
inbr
mous
strain
carri
spontan
activ
replicationcompet
endogen
virus
host
rang
mulv
control
part
interact
envelop
glycoprotein
cell
surfac
receptor
basi
cell
surfac
receptor
specif
differ
class
mulv
identifi
far
ecotrop
mulv
capabl
infect
mous
rat
cell
cultur
nonecotrop
mulv
may
xenotrop
xeno
foreign
infect
nonmous
speci
amphotrop
modifi
polytrop
infect
rang
host
includ
mice
mulv
induc
leukemia
mice
latenc
rang
month
depend
strain
viru
strain
mous
neonat
infect
far
effici
mean
leukemogenesi
wherea
infect
adult
leukemogen
virus
leukomogenesi
multistep
process
long
termin
repeat
ltr
activ
protooncogen
probabl
suppli
one
step
process
exampl
moloneymulv
induc
lymphoma
mice
rat
proviru
insert
activ
one
particular
set
protooncogen
although
activ
involv
use
replicationdefect
retrovir
vector
replicationcompet
mulv
also
develop
vector
platform
deliveri
gene
encod
prodrugactiv
cytosin
deaminas
cd
tumor
viru
tumorcel
specif
reli
mulv
depend
activ
cell
prolifer
product
infect
express
cancer
cell
cd
enzym
convert
prodrug
anticanc
drug
thu
sensit
tumor
mulvbas
replicationcompet
retrovir
rcr
vector
shown
yield
effici
gene
deliveri
cell
cultur
vivo
logg
colleagu
describ
develop
rcr
vector
harbor
intern
ribosom
entri
sitetransgen
gfp
cassett
posit
env
gene
ltr
vector
replic
effici
express
transgen
cultur
solid
tumor
model
vivo
analys
high
molecular
weight
dna
harvest
tumor
spleen
lung
kidney
liver
heart
reveal
presenc
fulllength
gfp
transgen
tumor
sampl
nontumor
tissu
data
show
spread
rcr
vector
appear
confin
tumor
tissu
also
tai
colleagu
show
transduct
rcr
vector
effici
tumorselect
persist
singl
dose
rcr
vector
express
cd
prodrugactiv
gene
follow
singl
cycl
inhibit
growth
preestablish
primari
glioma
mice
without
appar
damag
adjac
normal
brain
tissu
author
also
report
effici
rcr
vectormedi
transduct
malign
glioma
immunocompet
fisher
rat
use
rcr
vector
rais
question
possibl
pathogen
effect
result
spread
vector
host
although
mulv
known
induc
thymic
lymphoma
newborn
mice
pathogen
adult
mice
human
studi
amphotrop
mulv
requir
initi
studi
amphotrop
mulv
rhesu
monkey
could
find
evid
patholog
infect
anim
observ
period
despit
sever
immun
suppress
time
infect
administr
high
dose
replicationcompet
mulv
subsequ
studi
howev
reveal
amphotrop
replicationcompet
mulv
oncogen
primat
studi
rhesu
monkey
receiv
bonemarrow
cell
infect
replicationcompet
amphotrop
mulv
develop
tcell
lymphoma
result
suggest
mulv
potenti
oncogen
primat
presenc
normal
function
immun
system
reduc
oncogen
larg
extent
although
replicationdefect
deriv
mulv
use
frequent
genetransf
vector
clinic
gene
therapi
rel
littl
inform
avail
replicationcompet
amphotropicpseudotyp
mulv
primat
although
use
replicationdefect
mulv
gener
safe
well
toler
led
number
case
tcell
leukemia
develop
recipi
result
insert
mutagenesi
activ
protooncogen
express
use
replicationcompet
mulvderiv
vector
cancer
gene
therapi
novel
approach
despit
fact
mulv
presum
ineffici
transfer
horizont
human
uncertainti
surround
effect
replicationcompet
amphotrop
mulv
led
us
cautious
classifi
high
respect
rel
environment
risk
score
virus
place
neglig
rel
environment
risk
categori
autographa
californica
baculoviru
canarypox
viru
place
low
end
rel
environment
risk
spectrum
rel
risk
score
neglig
autographa
californica
baculoviru
narrow
host
rang
limit
singl
moth
speci
alfalfa
looper
autographa
californica
occur
western
half
north
american
contin
although
viru
transduc
cell
mani
mammalian
speci
baculoviru
gene
express
viral
genom
replic
human
blood
insect
cellproduc
viral
particl
rapidli
inactiv
human
complement
narrow
host
rang
viru
incapac
replic
mammalian
cell
therefor
limit
capac
viru
shed
patient
led
us
classifi
rel
environment
risk
baculovirus
neglig
alvacbas
canarypox
virus
host
rang
narrow
limit
canari
serinu
sp
also
alvacstrain
use
clinic
studi
strongli
attenu
natur
host
thu
alvacbas
canari
pox
vector
unlik
becom
threat
environ
sinc
viru
replic
mammalian
cell
viru
amplifi
shed
limit
initi
administ
dose
narrow
host
rang
viru
incapac
replic
human
cell
therefor
limit
capac
viru
shed
patient
led
us
classifi
rel
environment
risk
canarypox
viru
neglig
mani
preclin
studi
provid
proof
efficaci
oncolyt
viru
therapi
number
nonhuman
virus
test
earlyphas
clinic
studi
result
far
demonstr
feasibl
safeti
approach
anecdot
evid
antitumor
efficaci
aggreg
data
demonstr
often
sever
side
effect
haunt
initi
clinic
studi
oncolyt
virus
overcom
henc
field
move
forward
maintain
good
safeti
record
keep
trust
public
inde
reason
anticip
field
progress
clinic
use
nonhuman
therapeut
virus
expand
near
futur
activ
involv
genet
modifi
virus
legal
framework
permit
activ
usual
embed
nation
intern
eg
european
regul
compet
author
defin
procedur
well
establish
wide
known
field
procedur
obtain
permiss
clinic
applic
genet
modifi
virus
requir
proper
stepwis
environment
risk
assess
seem
desir
similar
stepwis
environment
risk
assess
also
perform
initi
clinic
applic
virus
consid
gmo
clinic
applic
nongenet
modifi
virus
fall
regul
pertain
genet
modifi
organ
uncertain
environment
risk
assess
formal
requir
use
initi
either
nation
level
intern
level
eg
european
level
regulatori
situat
clarifi
potenti
environment
impact
use
replicationcompet
nonhuman
virus
may
difficult
predict
without
reliabl
estim
potenti
environment
impact
may
difficult
obtain
consensu
requir
contain
measur
practic
procedur
risk
manag
clinic
applic
nonhuman
virus
essenti
rather
defin
set
strict
goal
bind
criteria
author
suggest
formul
list
point
consid
environment
risk
assess
list
could
use
defin
practic
procedur
facilit
applic
achiev
accept
risk
level
joint
respons
author
investig
defin
procedur
find
solut
assist
research
make
oncolyt
viru
therapi
power
approach
combat
cancer
